Adicet Bio, Inc. Files DEF 14A with Executive Compensation Details

TL;DR

<b>Adicet Bio, Inc. has filed its DEF 14A, detailing executive compensation adjustments for equity awards in fiscal year 2023.</b>

AI Summary

Adicet Bio, Inc. (ACET) filed a Proxy Statement (DEF 14A) with the SEC on April 23, 2024. Adicet Bio, Inc. filed a DEF 14A form on April 23, 2024. The filing covers the fiscal year ending December 31, 2023. It includes details on executive compensation adjustments for equity awards. Specific adjustments relate to year-end fair value, vesting dates, and dividends on equity awards. The company was formerly known as resTORbio, Inc., with a name change on October 24, 2017.

Why It Matters

For investors and stakeholders tracking Adicet Bio, Inc., this filing contains several important signals. This filing provides transparency into how executive compensation, particularly equity awards, is valued and adjusted, which is crucial for shareholder understanding and governance. The detailed breakdown of equity award adjustments, including fair value changes and dividend impacts, offers insight into the company's compensation philosophy and its potential effect on executive incentives.

Risk Assessment

Risk Level: low — Adicet Bio, Inc. shows low risk based on this filing. The filing is a routine DEF 14A, primarily focused on executive compensation disclosures, with no immediate financial or operational performance indicators presented.

Analyst Insight

Shareholders should review the executive compensation details to understand how equity awards are valued and adjusted, which can impact executive incentives and overall company governance.

Executive Compensation

Key Numbers

• 2023-12-31 — Fiscal Year End (Reporting period)
• 2024-04-23 — Filing Date (Date of submission)
• 2017-10-24 — Name Change Date (Former company name date)

Key Players & Entities

• Adicet Bio, Inc. (company) — Filer name
• ACET (company) — Ticker symbol
• DEF 14A (filing) — Form type
• 2024-04-23 (date) — Filing date
• resTORbio, Inc. (company) — Former company name
• 2017-10-24 (date) — Date of name change
• Chen Schor (person) — Executive mentioned in compensation adjustments

FAQ

Industry Context

Adicet Bio, Inc. operates in the pharmaceutical preparations industry, focusing on the development of allogeneic gamma delta T cell therapies for cancer and other diseases.

Regulatory Implications

The DEF 14A filing is a standard disclosure required by the SEC for public companies, particularly concerning annual meetings of shareholders and executive compensation.

What Investors Should Do

1. Review the detailed breakdown of equity award adjustments in the compensation tables.
2. Analyze the year-over-year changes in fair value for equity awards granted in prior years.
3. Understand the impact of dividends or other earnings on stock/option awards not otherwise reflected in fair value.

Key Dates

• 2024-04-23: DEF 14A Filing — Disclosure of executive compensation and corporate governance information.
• 2023-12-31: Fiscal Year End — Period covered by the compensation disclosures.
• 2017-10-24: Name Change — Transition from resTORbio, Inc. to Adicet Bio, Inc.

Year-Over-Year Comparison

This filing is a DEF 14A, which is a routine disclosure. No prior filing data for comparison is available in the provided text.

Key Financial Figures

• $0.0001 — 3 shares of our common stock, par value $0.0001 per share, outstanding on April 9, 2024

Filing Documents

• acet-20240423.htm (DEF 14A) — 1286KB
• img105727553_0.jpg (GRAPHIC) — 3KB
• img105727553_1.jpg (GRAPHIC) — 3KB
• img105727553_2.jpg (GRAPHIC) — 21KB
• img105727553_3.jpg (GRAPHIC) — 22KB
• img105727553_4.jpg (GRAPHIC) — 515KB
• img105727553_5.jpg (GRAPHIC) — 179KB
• 0000950170-24-047034.txt (&nbsp;) — 3791KB
• acet-20240423.xsd (EX-101.SCH) — 40KB
• acet-20240423_htm.xml (XML) — 236KB

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 38 PAY VERSUS PERFORMANCE 47 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS 50 PRINCIPAL STOCKHOLDERS 52 REPORT OF THE AUDIT COMMITTEE 56 HOUSEHOLDING 57 STOCKHOLDER PROPOSALS 57 OTHER MATTERS 57 ANNEX A – AMENDMENT NO. 1 TO ADICET BIO, INC. SECOND AMENDED AND RESTATED 2018 STOCK OPTION AND INCENTIVE PLAN 58 ANNEX B – CERTIFICATE OF AMENDMENT – INCREASE IN AUTHORIZED SHARES 71 ANNEX C – CERTIFICATE OF AMENDMENT – OFFICER EXCULPATION 72 i ADICET BIO, INC. 131 Dartmouth Street, 3rd Floor Boston, Massachusetts 02116 PROXY STATEMENT FOR THE 2024 ANNUAL MEETING OF STOCKHOLDERS to be held JUNE 5, 2024 This proxy statement for the 2024 annual meeting of stockholders (Proxy Statement) contains information about the 2024 Annual Meeting of Stockholders (Annual Meeting) of Adicet Bio, Inc., which will be held online on June 5, 2024 at 5:00 p.m. Eastern Time. You may attend the Annual Meeting virtually via the Internet at www.virtualshareholdermeeting.com/ACET2024 , where you will be able to vote electronically and submit questions. The board of directors of Adicet Bio, Inc. is using this Proxy Statement to solicit proxies for use at the Annual Meeting. In this Proxy Statement, the terms "Company," "Adicet Bio," "Adicet," "we," "us," and "our" refer to Adicet Bio, Inc. The mailing address of our principal executive office is Adicet Bio, Inc., 131 Dartmouth Street, 3rd Floor, Boston, Massachusetts 02116. All properly submitted proxies will be voted in accordance with the instructions contained in those proxies. If no instructions are specified, the proxies will be voted in accordance with the recommendation of our board of directors with respect to each of the matters set forth in the accompanying Notice of Meeting. You may revoke your proxy at any time before it is exercised at the meeting by giving our corporate secretary written notice to that effect. This year's Annual Meeting will be

View Full Filing

View this DEF 14A filing on SEC EDGAR